Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Microdosing with MK-0482 and MK-4830 in HNSCC/STS
NCT06413095Phase 1Completed
- Sponsor
- Presage Biosciences
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab, rolistobart and mk-4830 in head and neck squamous cell carcinoma (HNSCC) and soft tissue sarcoma (STS), sponsored by Presage Biosciences. Primary endpoint: Quantification of Immune Cell Biomarkers. Started Jun 2022; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06413095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06413095.